



Mission of AABC

The mission of the Alzheimer's Association Business Consortium (AABC) is to advance Alzheimer's disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

AABC members work in areas of common interest pre-competitively to advance both the field of Alzheimer's research and the goals of its member organizations. They provide leadership and direction to the group's areas of focus, which include, but are not limited to, collaborations, recognition and visibility, and knowledge and information sharing. AABC welcomes new members who are aligned in their commitment to research and innovation. To express interest in joining, please email [Dr. Judy Walker](#), [Joseph Araujo](#), co-chairs, or [Dr. Christopher Weber](#), facilitator.



Welcome to our New Members

AABC is growing! Welcome to:

- » **Owen Phillips, William Ogden Moore & Ben Kotopka, BrainKey.** [BrainKey](#), is a health care startup with a tech core based in San Francisco. We empower people to understand their brains by building personalized 3D brain visualizations and offering statistical analytics based on the individual's MRI.
- » **Jacob Donoghue (Founder, CEO), Brandon Westover (Founder), Syd Cash (Founder), & Jarrett Revels (Founder, CTO), Beacon Biosignals.** [Beacon Biosignals](#) which applies state-of-the-art machine learning algorithms to EEG for improved diagnosis, treatment selection, and patient stratification in neurological and psychiatric disease.



News from AABC Members



Amylyx Pharmaceuticals nabs \$30M for ALS, Alzheimer's work

After posting positive data that showed it could help slow down amyotrophic lateral sclerosis (ALS), Amylyx Pharmaceuticals has been given a \$30 million boost. Its leading candidate, AMX0035, is being tested in degenerative ALS and Alzheimer's disease, two very tough targets with a long history of failures. The drug, however, recently came through the so-called CENTAUR test demonstrating it could slow disease progression when compared to placebo. Full data from the phase 2 trial are expected in "the near term," but, in the meantime, Amylyx is also working on a midstage trial for the drug called PEGASUS in Alzheimer's, with top-line data slated for the first quarter next year. Morningside Ventures as well as other investors bet \$30 million it can, and contributed to the company's biggest single funding round since its 2013 launch. Its methodology targets mitochondrial and endoplasmic reticulum dependent neuronal degeneration pathways.



Annovis Bio Actively Recruiting and Treating Patients in Phase 2a Study in Alzheimer's and Parkinson's Diseases

Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, is actively recruiting and treating early AD and PD patients in its new Phase 2a clinical trial. The two-part study, which received IRB approval in July 2020, is designed to treat a combined total of 28 AD and PD patients for four weeks with Annovis' lead compound, ANVS401. The study compares in both patient populations how nerve cells die by measuring all the steps in the toxic cascade leading to nerve cell death and how ANVS401 might reverse the toxic cascade and recover normal brain function. In addition to target and pathway

engagement, the Phase 2a study also examines safety and tolerability as well as the effect of ANVS401 on motor impairment and non-motor symptoms in early PD patients and the effect on memory and cognitive function in early AD subjects. The company recruited and began treating its first three patients in the study in late August 2020. The study is planned to be recruiting in 15 sites and expected to have preliminary data by early next year with a dose response study in 40 additional patients expected to be completed in the third quarter of 2021. The company is following all recommended protocols and taking appropriate precautions regarding COVID-19 and has selected the 15 sites to be geographically dispersed throughout the U.S. The company also restarted recruitment of its first Phase 2a study in AD patients after pausing the study earlier this year due to COVID-19. This study is being conducted at six sites. Prior to suspension of enrollment, 14 patients had been enrolled and treated in this trial; patient 15 was enrolled at the end of August.



T3D Therapeutics Receives a Research Award from the Alzheimer's Association Part the Cloud-Gates Partnership Grant Program

T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer's disease (AD), announced today that it has received a \$740,000 grant from the Alzheimer's Association Part the Cloud-Gates Partnership Grant Program in support of clinical trial biomarker studies. These biomarker studies are an integral part of the upcoming Phase 2 clinical study of T3D-959, a novel, metabolic-focused AD drug treatment.

The Phase 2 PIONEER study (Prospective therapy to Inhibit and Overcome Alzheimer's Disease Neurodegeneration via Brain EnErgetics and Metabolism Restoration) is expected to initiate patient dosing in early 2021. PIONEER is a double-blind, placebo-controlled, parallel-group Phase 2 safety and efficacy study expected to enroll up to 252 adults with mild-to-moderate Alzheimer's disease (MMSE 16-26). PIONEER will enroll subjects who will receive one of three different doses of T3D-959 or a placebo for 24 weeks.

"It is an honor to have won this highly competitive award from the Alzheimer's Association Part the Cloud-Gates Partnership Grant Program and the recognition that improving inherent metabolic defects in Alzheimer's disease is a vital and largely unexplored therapeutic avenue to treat AD," says Chief Executive Officer John Didsbury, Ph.D.



Virtual Events

Continuing to Serve Small Businesses During the Pandemic

The National Institute on Aging Office of Small Business Research (OSBR) is adapting and working hard to support small companies, entrepreneurship and innovation during the COVID-19 pandemic. Apply now for two new funding opportunities to address family caregiving and geroscience, or connect virtually to help grow your business. [Read the full blog post.](#)

The [NIA OSBR](#) offers opportunities to connect and learn about small business funding. Follow them on [LinkedIn](#) for additional networking opportunities for grantees and investors.

Support the Next Generation of Neuroscientists

AAIC Neuroscience Next — November 9-10, 2020 — is a unique, no-cost event that will showcase the work of neuroscience students and early career investigators and provide opportunities to make an impact in dementia research. Please tell students and early career investigators in your network about this conference, and join us to hear from up-and-coming neuroscientists. [Register today at no cost.](#)



Past Events

Alzheimer's Disease Genetics Global Symposium

On September 22, the virtual Alzheimer's Disease Genetics Global Symposium brought together members of the global dementia science community for a live discussion of developments in Alzheimer's genetics research. If you weren't able to attend, [register now at no cost](#) to view webinars through September 22, 2021.

AAIC 2020

With over 33,000 registrants representing more than 160 countries, the virtual Alzheimer's Association International Conference® 2020 (AAIC®) extended the Association's reach and expanded the breadth of science presented. The conference featured over 60 hours of live sessions, more than 130 hours of on-demand content and over 2,800 posters – at no cost to attendees. The conversations and exchanges that happen at AAIC help to advance our collective efforts. To learn more, visit alz.org/AAIC.

AABC Meeting at AAIC 2020

Consortium members discussed ideas to make the AABC more effective for its memberships at the virtual AAIC 2020 in July. Dr. Michael Canney, Scientific Director at CarThera, presented CarThera's technology to the consortium. The meeting summary is available on the [AABC website](#).

Elections

AABC will hold elections for a new co-chair to replace Dr. Judy Walker. This position will serve with current co-chair Joseph Araujo for two years beginning in January. A call for nominations is starting now and voting will take place in November. Self-nominations are accepted.

The co-chair responsibilities include:

- » Monthly calls with Alzheimer's Association staff Christopher Weber and Ashley Hansen to plan future events, propose new webinar topics, suggest speakers and discuss new directions.
- » Participate in webinars and in-person events.
- » Review and edit quarterly newsletters.
- » Provide leadership and guidance on AABC topics and issues, as time allows.

Each company is allowed only ONE vote. If there are several members from the same company; please identify one representative to provide the consensus on the company's behalf. Individuals must be a member of AABC to vote.

Social Media

Follow Us on LinkedIn

AABC is on LinkedIn! Please visit the new [page](#) and request to join. We look forward to using the page to foster partnerships and communications.

We are looking for a communications liaison to help set up and manage the new LinkedIn page and reach current and prospective members. If interested, please contact [Ashley Hansen](#).

Alzheimer's Association Science Hub App



The Science Hub provides the latest news right in the palm of your hand. This trusted tool distributes research, spreads awareness and delivers accurate information directly to your phone.

Learn more at alz.org/sciencehub, or search "Science Hub" in your app store.

Spread the Word

To help us grow AABC, please continue to introduce new members and companies to our group. We also welcome ideas or events for this newsletter so we can better serve you. Please send your suggestions to [Ashley Hansen](#).